Stock Events

Stock Events

Prime Medicine 

$3.41
183
-$0.06-1.73% 12:16 Today

Statistics

Day High
3.49
Day Low
3.48
52W High
6.94
52W Low
2.67
Volume
111,450
Avg. Volume
-
Mkt Cap
630.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 19
$0.80
Jun 19
$0.20
Dec 18
$0.21
Sep 18
$0.23
Jun 18
$0.15
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.44
-0.38
-0.31
-0.25
Expected EPS
-0.257241
Actual EPS
N/A

Financials

-4,342.44%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
4.63MRevenue
-201.14MNet Income

Analyst Ratings

9.50Average Price Target
The highest estimate is 11.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRME. It's not an investment recommendation.
Rocket Lab
49
RKLB
NVIDIA
45
NVDA
AST SpaceMobile
40
ASTS
Palantir Technologies
37
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics is a leader in the development of gene-based medicine, directly competing with Prime Medicine's gene editing technology.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine focuses on developing CRISPR gene editing treatments, making it a direct competitor in the gene therapy space.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics is known for its advancements in CRISPR/Cas9 technology for gene editing, competing in the same field as Prime Medicine.
Beam Therapeutics
BEAM
Mkt Cap3.36B
Beam Therapeutics uses base editing, a form of gene editing that competes with Prime Medicine's technology for precision and reduced off-target effects.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics works on genome editing and gene therapy, including zinc finger nuclease technology, offering alternatives to Prime Medicine's approaches.
Pacific Biosciences of California
PACB
Mkt Cap484.54M
Pacific Biosciences offers long-read sequencing technologies that are crucial for gene editing research, indirectly competing by enabling gene editing advancements.
Twist Bioscience
TWST
Mkt Cap5.64B
Twist Bioscience operates in the synthetic biology space, providing tools and technologies that support gene editing, thus indirectly competing with Prime Medicine.

Holdings

Regions

Sectors

About

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Show more...
CEO
Mr. Jeffrey D. Marrazzo M.B.A., M.P.A.
Employees
146
Country
United States
ISIN
US74168J1016

Listings

BOATS
BOATS
PRME.BOATS
XNAS
US
PRME

0 Comments

Share your thoughts

FAQ

What is Prime Medicine stock price today?▼
The current price of PRME is $3.41 USD — it has decreased by -1.73% in the past 24 hours. Watch Prime Medicine stock price performance more closely on the chart.
What is Prime Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Prime Medicine stocks are traded under the ticker PRME.
Is Prime Medicine stock price growing?▼
PRME stock has fallen by -17.49% compared to the previous week, the month change is a +21.6% rise, over the last year Prime Medicine has showed a -13.61% decrease.
What is Prime Medicine market cap?▼
Today Prime Medicine has the market capitalization of 630.35M
When is the next Prime Medicine earnings date?▼
Prime Medicine is going to release the next earnings report on August 06, 2026.
What were Prime Medicine earnings last quarter?▼
PRME earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.25 USD resulting in a -11.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Prime Medicine revenue for the last year?▼
Prime Medicine revenue for the last year amounts to 4.63M USD.
What is Prime Medicine net income for the last year?▼
PRME net income for the last year is -201.14M USD.
Does Prime Medicine pay dividends?▼
Yes, PRME dividends are paid quarterly. The last dividend per share was 0.8 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Prime Medicine have?▼
As of July 16, 2026, the company has 146 employees.
In which sector is Prime Medicine located?▼
Prime Medicine operates in the Health & Wellness sector.
When did Prime Medicine complete a stock split?▼
Prime Medicine has not had any recent stock splits.
Where is Prime Medicine headquartered?▼
Prime Medicine is headquartered in Cambridge, United States.